PMID- 20698249
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20161125
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 57
IP  - 99-100
DP  - 2010 May-Jun
TI  - Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) 
      during treatment with proton pump inhibitors, and the suppressive effects of 
      polaprezinc.
PG  - 678-84
AB  - BACKGROUND/AIMS: When a peptic ulcer is treated with proton pump inhibitors 
      (PPI), protrusion of the ulcer base is sometimes noted during ulcer healing. To 
      clarify the incidence of ulcer base protrusion in ulcers induced by endoscopic 
      submucosal dissection (ESD), and whether the addition of polaprezinc, a 
      cytoprotective agent used for treatment of gastric ulcer, to the PPI regimen 
      helps to suppress it. METHODOLOGY: One hundred sixty-three patients on which ESD 
      was performed were randomly allocated to either two groups: one treated with 
      lansoprazole (30mg/day) and the other with lansoprazole (30mg/day) plus 
      polaprezinc (150mg/day) for the treatment of ESD-induced ulcer. The condition of 
      the ESD-induced ulcer was blindly assessed two months after ESD by two 
      physicians. RESULTS: Lansoprazole plus polaprezinc group showed significantly 
      better ulcer healing (p < 0.0001) and protrusion of the ulcer base was recognized 
      in only 1.3% (1/77), an incidence significantly lower than that in lansoprazole 
      group (20.7%, 16/77, p = 0.0001). Polaprezinc was the only significant factor (p 
      = 0.0001) differentiating patients who had ulcer base protrusion (n = 17) from 
      those who did not (n = 137). CONCLUSIONS: Polaprezinc prevents protrusion of the 
      ulcer base during the healing of ESD-induced ulcer with PPI.
FAU - Inaba, Tomoki
AU  - Inaba T
AD  - Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, 
      Kagawa 760-8557, Japan. t-inaba@chp-kagawa.jp
FAU - Ishikawa, Shigenao
AU  - Ishikawa S
FAU - Toyokawa, Tatsuya
AU  - Toyokawa T
FAU - Ishikawa, Hisashi
AU  - Ishikawa H
FAU - Miyahara, Koji
AU  - Miyahara K
FAU - Wato, Masaki
AU  - Wato M
FAU - Kawai, Kozo
AU  - Kawai K
FAU - Okada, Hiroyuki
AU  - Okada H
FAU - Yamamoto, Kazuhide
AU  - Yamamoto K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Zinc Compounds)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 0WA1B15A1Z (polaprezinc)
RN  - 8HO6PVN24W (Carnosine)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/*therapeutic use
MH  - Aged
MH  - Carnosine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Cytoprotection
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastric Mucosa/*surgery
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Organometallic Compounds/administration & dosage/*therapeutic use
MH  - Postoperative Complications/*drug therapy
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Stomach Neoplasms/*surgery
MH  - Stomach Ulcer/*drug therapy/etiology/pathology
MH  - Wound Healing
MH  - Zinc Compounds/administration & dosage/therapeutic use
EDAT- 2010/08/12 06:00
MHDA- 2010/09/09 06:00
CRDT- 2010/08/12 06:00
PHST- 2010/08/12 06:00 [entrez]
PHST- 2010/08/12 06:00 [pubmed]
PHST- 2010/09/09 06:00 [medline]
PST - ppublish
SO  - Hepatogastroenterology. 2010 May-Jun;57(99-100):678-84.